Alumis Inc. Common Stock

NASDAQ:ALMS

Biotechnology

Healthcare
$4.40 +0.91%

+$0.21 today

Market cap
$568.87M
Beta
-0.54
P/E (TTM)
-12.2
EPS (TTM)
-$1.90
52W Low $2.76High $30.60

Volume 2.01M

Average 1.31M

ALMS Deferred Income Tax

The difference between tax expense recognized and tax actually paid in cash during the period.

Alumis Inc. Common StockNASDAQ: ALMS

Deferred Income Tax · Q2 FY2026 · quarter ended Jun 2026

Deferred income tax turns negative

Q2 FY2026 deferred income tax was -$1.76M, compared with $0 a year earlier. Trailing-twelve-month deferred income tax was -$10.32M.

Context

  • Deferred income tax amounted to 35.6% of revenue in FY2025.
  • Deferred income tax increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly deferred income tax holds near -$1.76M or moves back toward the trailing-twelve-month quarterly average of -$2.58M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$1.76M— QoQ
Last fiscal yearDec 2025
-$8.56M— YoY
LTMJun 2026
-$10.32M— YoY
Deferred Income Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Income Tax history

USD · from the cash flow

Latest · FY2025
(8.56M) USD
Year-over-year change
—

Deferred Income Tax vs competitors

How ALMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so deferred income tax is compared through growth and share of revenue rather than absolute size.
  • Deferred income tax amounts to 139.5% of revenue for ALMS, versus a peer median of 0.0%.
ALMS Competitors
Deferred Income Tax for ALMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$243.28M USD——81.2%
ALMSAlumis Inc. Common StockLTM Jun 2026$10.32M USD——139.5%
AVTXAvalo Therapeutics, Inc.LTM Mar 2026$678K USD+272.1%+80.6%1149.2%
ANABAnaptysBio, Inc.LTM Mar 2026$0 USD——0.0%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$0 USD———
IFRXInflaRx N.V.LTM Mar 2026€0 EUR——0.0%
TLSATiziana Life Sciences LtdFY2025$0 USD———
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$0 USD———
ODTXOdyssey Therapeutics, Inc.—— ———
AGMBAgomAb Therapeutics N.V. American Depositary Shares—— ———
Peer median (excluding ALMS) —+272.1%+80.6%0.0%

Competitors are the stored peer set for ALMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(111.93M)(154.99M)(294.23M)(243.33M)
Depreciation & Amortization250K1.28M3.15M3.5M
Deferred Income Tax000(8.56M)
Stock-Based Compensation5.96M8.63M19.46M43.52M
Change in Working Capital(1.92M)12.06M14.76M26.32M
Accounts Receivables0000
Inventory0000
Accounts Payables1.29M(642K)8.51M(6.04M)
Other Working Capital(3.21M)12.7M6.25M32.35M
Other Non-Cash Items(86K)3.05M1.79M(190.98M)
Operating Cash Flow(107.72M)(129.98M)(255.08M)(369.52M)
Capital Expenditures(2.41M)(4.5M)(1.73M)(653K)
Acquisitions (Net)0000
Purchases of Investments(209.08M)(11.28M)(240.06M)(209.17M)
Sales of Investments142.73M76.25M128M447.96M
Other Investing Activities00049.74M
Investing Cash Flow(68.75M)60.47M(113.79M)287.88M
Debt Repayment0000
Common Stock Issued00193.32M2.08M
Common Stock Repurchased000(17K)
Dividends Paid0000
Other Financing Activities1.73M(96K)40.59M0
Financing Cash Flow101.63M89.68M492.37M2.07M
Effect of Forex Changes0000
Net Change in Cash(74.85M)20.18M123.5M(79.58M)
Free Cash Flow(110.13M)(134.47M)(256.81M)(370.18M)

Alumis Inc. Common Stock

NASDAQ:ALMS

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.